SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is experiencing significant volatility and retail scrutiny following the company's announcement of a $1.4 billion convertible debt-for-equity swap. The community remains deeply divided, with some investors viewing the move as a strategic balance sheet cleanup ahead of potential M&A activity, while others criticize management for diluting existing shareholders and failing to deliver on long-term performance expectations.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is currently the focus of intense investor attention as an FDA advisory committee evaluates the efficacy of its lead cancer therapy, RP1, following past regulatory setbacks. Community discussion is sharply divided between those betting on a successful approval as a major catalyst for a short squeeze and skeptics pointing to FDA briefing documents, potential dilution, and the history of prior rejections.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors react to a positive quarterly earnings report, with the community actively debating the company's rapid store expansion and margin efficiency despite ongoing concerns about the stock's OTC status. Long-term shareholders remain highly optimistic, contrasting growth metrics against short-sellers and speculating on the potential for a future major exchange relisting.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is experiencing a surge in investor attention and high-stakes options activity ahead of its upcoming earnings report, with the community closely tracking the company's progress in scaling autonomous delivery operations and physical AI. Traders are actively debating the potential for a short squeeze, fueled by significant short interest and speculation regarding future enterprise partnerships or a potential buyout, as bullish sentiment grows around the firm's expansion into new markets.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors remain bullish on the company's trajectory toward hitting one billion dollars in annual revenue, with the community closely tracking the potential of its Briumvi franchise in multiple sclerosis and its pipeline expansion into schizophrenia and myasthenia gravis. While recent price target hikes have sparked conversation, the core discussion revolves around a strong commercial execution and the potential for a strategic acquisition, leading many long-term shareholders to dismiss near-term volatility and shortsellers as they anticipate further growth.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is seeing intense investor focus following a string of major capacity-reservation agreements with industry giants, fueling a debate over whether these deals signal a fundamental inflection point for its semiconductor substrates or if the stock's valuation has detached from its near-term financials. Community discussion remains polarized, with some traders betting on a significant short squeeze and long-term photonics demand, while others caution against high-beta volatility and ongoing export permit risks.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors eagerly await Phase 3 IZAR-1 clinical trial results, with community speculation heavily focused on whether the data release will coincide with upcoming quarterly earnings. The stock is currently subject to intense discussion regarding its potential as a 'best-in-class' treatment for psoriatic arthritis, with many market participants viewing the current price consolidation as a strategic entry point before a anticipated major catalyst.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant investor attention following a series of upsized, high-rated ABS deals and sustained institutional interest, fueling bullish sentiment around its AI-driven credit underwriting model. The community is actively discussing the company's strong fundamentals and potential for a short squeeze, with many focusing on whether the stock can maintain its momentum toward higher resistance levels despite broader fintech sector volatility.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers Squibb is capturing significant market attention following a high-profile report that AstraZeneca is exploring a massive $400 billion merger with the company. Investors are actively debating the potential for industry-wide pharmaceutical consolidation, while others remain focused on the strategic implications for BMY's oncology pipeline and the likelihood of significant cost-cutting synergies.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is currently at the center of market attention due to reports of potential merger talks with Bristol Myers Squibb in a deal that could be valued at approximately $400 billion. Investors are actively debating the potential for portfolio synergies in oncology, while the market remains sensitive to the inherent risks and antitrust complications associated with a transaction of this magnitude.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare

Pacira gains a reimbursement boost as UnitedHealthcare separately covers Exparel in outpatient care, expanding access to non-opioid postsurgical pain treatment.

Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal

PCRX is set to sell its iovera franchise to ZBH in a deal worth up to $140M as it sharpens focus on biopharmaceutical growth.

Pacira To Sell Iovera Business To Zimmer Biomet; Pacira Shares Up

(RTTNews) - Pacira BioSciences Inc. (PCRX) on Tuesday announced an agreement to divest its iovera business to Zimmer Biomet Holdings (ZBH) for up to $140 million...

Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting

Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting PR Newswire BRISBANE, Calif., June 9, 2026 BRISBANE, Calif...

Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting

Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of...

Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees

Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees PR Newswire BRISBANE...

DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION

DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION PR...

A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC

A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC PR Newswire MIAMI, May 21, 2026 FRANK LEE AND THE BOARD HAVE OVERSEEN GROSS AND PERSISTENT UNDERPERFORMANCE FOR YEARS. WHY...

DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences

DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences PR Newswire MIAMI, May 20, 2026 Independent Directors, Christopher Dennis, MD, MBA, FAPA and Oliver Benton "Ben" Curtis III Outline...

Royal Bank Of Canada Issues Positive Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock Price

Royal Bank Of Canada raised their price target on shares of Pacira BioSciences from $22.00 to $24.00 and gave the company a "sector perform" rating in a research report on Friday...

$PCRX Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.07 down -30.00% YoY
• Reported revenue of $177.38M up 5.00% YoY

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Brisbane, CA.

Pacira BioSciences Inc

Pacira Biosciences Stock Rises On Multiple Price Target Upgrades: Retail Sentiment Soars

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

PCRXPacira BioSciences Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest PCRX News